Bibliography
- Mehnert W , MaderK: Solid lipid nanoparticles. Production, characterization and applications.Adv. Drug Deliv. Rev.47(2–3), 165–196 (2001).
- Wissing SA , KayserO, MullerRH: Solid lipid nanoparticles for parenteral drug delivery.Adv. Drug Deliv. Rev.56(9), 1257–1272 (2004).
- Montana G , BondìML, CarrottaRet al.: Employment of cationic solid-lipid nanoparticles as RNA carriers.Bioconjugate Chem.18(2), 302–307 (2007).
- Chen D , YangT, LiangWet al.: In vitro and in vivo study of two types of long circulating solid lipid nanoparticles containing paclitaxel.Chem. Pharm. Bull.49(11), 1444–1447 (2001).
- Reddy JS , VenkateswarluV: Novel delivery systems for drug targeting to the brain.Drugs Future29(1), 63–83 (2004).
- Yang S , ZhuJ, LuYet al.: Body distribution of camptothecin solid lipid nanoparticles after oral administration.Pharm. Res.16(5), 751–757 (1999).
- Kreuter J : Nanoparticulate systems for brain delivery of drugs.Adv. Drug Deliv. Rev.47(1), 65–81 (2001).
- Kaur IP , BhandariR, BhandariSet al.: Potential of solid lipid nanoparticles in brain targeting.J. Control. Rel.127(2), 97–109 (2008).
- Joshi MD , MüllerRH: Lipid nanoparticles for parenteral delivery of actives.Eur. J. Pharm. Biopharm.71(2), 161–172 (2009).
- Miller RG , MitchellJD, LyonMet al.: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).Cochrane Database Syst. Rev.1, CD001447 (2007).
- Storch A , BurkhardtK, LudolphACet al.: Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism.J. Neurochem.75(6), 2259–2269 (2000).
- Louhimies S : Directive 86/609/EEC on the protection of animals used for experimental and other scientific purposes.Altern. Lab. Anim.30(Suppl. 2), 217–219 (2002).
- Issazadeh S , LorentzenJC, MustafaMIet al.: Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-β.J. Neuroimmunol.69(1–2), 103–115 (1996).
- Bondì ML , CraparoEF, GiammonaGet al.: Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies.Drug Deliv.14(2), 61–67 (2007).
- Lockman PR , KoziaraJ, RoderKEet al.: In vivo and in vitro assessment of baseline blood–brain barrier parameters in the presence of novel nanoparticles.Pharm. Res.20(5), 705–713 (2003).
- Kerlero de Rosbo N , MendelI, Ben-NunA: Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PLJ mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes.Eur. J. Immunol.25(4), 985–993 (1995).
Patents
- Muller RH, Lucks JS: EP-0605497 (1996).
- Bondì ML, Craparo EF, Giammona G, Drago F: WO2008/000448 A2 (2008).